NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1243.90 3.70 (0.30%)

164.4K NSE+BSE Volume

NSE 17 Oct, 2025 10:27 AM (IST)

103,817.6

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Dr. Reddy's Laboratories Ltd. is on 24 Oct 2025 for the purpose of Quarterly Results See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1243.90

0.30%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1240.3

Dr. Reddy's Laboratories Ltd.

29 Jul 2025

1243.90

0.30%

Price Erosion across the US portfolio to remain the key overhang for its overall business

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.

Dr. Reddy's Laboratories Ltd.'s price crossed above 200Day SMA today

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1243.90

0.30%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1271.9

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1243.90

0.30%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Axis Direct

We maintain our HOLD recommendation on with a target price of Rs 1,360/share, implying an upside potential of 9% from the CMP.

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1240.3

Dr. Reddy's Laboratories Ltd.

23 Jul 2025

1243.90

0.30%

Out-licensing income/lower R&D spend drive better-thanexpected EBITDA

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) reported sales in line with our estimates in 1QFY26, while EBITDA/PAT came in higher than expected, primarily led by higher outlicensing income and lower R&D expenses.

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1271.9

Dr. Reddy's Laboratories Ltd.

07 Jul 2025

1243.90

0.30%

DR. REDDY'S LABORATARIES

Sell: Dr. Reddy's Laboratories Ltd.

Geojit BNP Paribas

*over or under performance to benchmark index Dr. Reddy's Laboratories (Dr. Reddy's) is an Indian pharmaceuticals company that manufactures and markets more than 190 medications, 180+ active pharmaceutical...

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

12 May 2025

1243.90

0.30%

Dr. Reddy's Laboratories (DRRD IN) Q4FY25 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q4FY25 EBITDA was below our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from current level of 16% to +20% in FY27E. Our FY27E EPS stands cut by 4-5%. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and...

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1271.9

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1243.90

0.30%

Core US business weakness coming to the fore

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.

Dr. Reddy's Laboratories Ltd.'s price crossed above 200Day SMA today

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1243.90

0.30%

Soft g-Revlimid sales, high expenses dent earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFy25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market